|
1
|
Cao H, Xu E, Liu H, Wan L and Lai M:
Epithelial-mesenchymal transition in colorectal cancer metastasis:
A system review. Pathol Res Pract. 211:557–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kang KA, Piao MJ, Ryu YS, Hyun YJ, Park
JE, Shilnikova K, Zhen AX, Kang HK, Koh YS, Jeong YJ and Hyun JW:
Luteolin induces apoptotic cell death via antioxidant activity in
human colon cancer cells. Int J Oncol. 51:1169–1178. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brownlee M: Advanced protein glycosylation
in diabetes and aging. Annu Rev Med. 46:223–234. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hori O, Yan SD, Ogawa S, Kuwabara K,
Matsumoto M, Stern D and Schmidt AM: The receptor for advanced
glycation end-products has a central role in mediating the effects
of advanced glycation end-products on the development of vascular
disease in diabetes mellitus. Nephrol Dial Transplant. 11 (Suppl
5):S13–S16. 1996. View Article : Google Scholar
|
|
6
|
Schmidt AM, Yan SD, Wautier JL and Stern
D: Activation of receptor for advanced glycation end products: A
mechanism for chronic vascular dysfunction in diabetic vasculopathy
and atherosclerosis. Circ Res. 84:489–497. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bao JM, He MY, Liu YW, Lu YJ, Hong YQ, Luo
HH, Ren ZL, Zhao SC and Jiang Y: AGE/RAGE/Akt pathway contributes
to prostate cancer cell proliferation by promoting Rb
phosphorylation and degradation. Am J Cancer Res. 5:1741–1750.
2015.PubMed/NCBI
|
|
8
|
Lee KJ, Yoo JW, Kim YK, Choi JH, Ha TY and
Gil M: Advanced glycation end products promote triple negative
breast cancer cells via ERK and NF-κB pathway. Biochem Biophys Res
Commun. 495:2195–2201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neviere R, Yu Y, Wang L, Tessier F and
Boulanger E: Implication of advanced glycation end products (Ages)
and their receptor (Rage) on myocardial contractile and
mitochondrial functions. Glycoconj J. 33:607–617. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun L, Huang T, Xu W, Sun J, Lv Y and Wang
Y: Advanced glycation end products promote VEGF expression and thus
choroidal neovascularization via Cyr61-PI3K/AKT signaling pathway.
Sci Rep. 7:149252017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nasser MW, Wani NA, Ahirwar DK, Powell CA,
Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, et al: RAGE
mediates S100A7-induced breast cancer growth and metastasis by
modulating the tumor microenvironment. Cancer Res. 75:974–985.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qin Q, Niu J, Wang Z, Xu W, Qiao Z and Gu
Y: Heparanase induced by advanced glycation end products (AGEs)
promotes macrophage migration involving RAGE and PI3K/AKT pathway.
Cardiovasc Diabetol. 12:372013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li G, Xu J and Li Z: Receptor for advanced
glycation end products inhibits proliferation in osteoblast through
suppression of Wnt, PI3K and ERK signaling. Biochem Biophys Res
Commun. 423:684–689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karin M, Yamamoto Y and Wang QM: The IKK
NF-kB system: A treasure trove for drug development. Nat Rev Drug
Discov. 3:17–26. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimomoto T, Luo Y, Ohmori H, Chihara Y,
Fujii K, Sasahira T, Denda A and Kuniyasu H: Advanced glycation end
products (AGE) induce the receptor for AGE in the colonic mucosa of
azoxymethane-injected Fischer 344 rats fed with a high-linoleic
acid and high-glucose diet. J Gastroenterol. 47:1073–1083. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen H, Wu L, Li Y, Meng J, Lin N, Yang D,
Zhu Y, Li X, Li M, Xu Y, et al: Advanced glycation end products
increase carbohydrate responsive element binding protein expression
and promote cancer cell proliferation. Mol Cell Endocrinol.
395:69–78. 2015. View Article : Google Scholar
|
|
20
|
Grote VA, Nieters A, Kaaks R, Tjønneland
A, Roswall N, Overvad K, Nielsen MR, Clavel-Chapelon F,
Boutron-Ruault MC, Racine A, et al: The associations of advanced
glycation end products and its soluble receptor with pancreatic
cancer risk: A case-control study within the prospective EPIC
cohort. Cancer Epidemiol Biomarkers Prev. 21:619–628. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takino J, Yamagishi S and Takeuchi M:
Glycer-AGEs-RAGE signaling enhances the angiogenic potential of
hepatocellular carcinoma by upregulating VEGF expression. World J
Gastroenterol. 18:1781–1788. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishibashi Y, Matsui T, Takeuchi M and
Yamagishi S: Metformin inhibits advanced glycation end products
(AGEs)-induced growth and VEGF expression in MCF-7 breast cancer
cells by suppressing AGEs receptor expression via AMP-activated
protein kinase. Horm Metab Res. 45:387–390. 2013.PubMed/NCBI
|
|
23
|
Chen H, Li Y, Zhu Y, Wu L, Meng J, Lin N,
Yang D, Li M, Ding W, Tong X and Su Q: Advanced glycation end
products promote ChREBP expression and cell proliferation in liver
cancer cells by increasing reactive oxygen species. Medicine
(Baltimore). 96:e74562017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X, Liu K, Wang Z, Liu C, Han Z, Tao J,
Lu P, Wang J, Wu B, Huang Z, et al: Advanced glycation end products
accelerate arteriosclerosis after renal transplantation through the
AGE/RAGE/ILK pathway. Exp Mol Pathol. 99:312–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Foster D, Spruill L, Walter KR, Nogueira
LM, Fedarovich H, Turner RY, Ahmed M, Salley JD, Ford ME, Findlay
VJ and Turner DP: AGE metabolites: A biomarker linked to cancer
disparity? Cancer Epidemiol Biomarkers Prev. 23:2186–2191. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vlassara H and Uribarri J: Advanced
glycation end products (AGE) and diabetes: Cause, effect, or both?
Curr Diab Rep. 14:4532014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duan Z, Chen G, Chen L,
Stolzenberg-Solomon R, Weinstein SJ, Mannisto S, White DL, Albanes
D and Jiao L: Determinants of concentrations of
N(ε)-carboxymethyl-lysine and soluble receptor for advanced
glycation end products and their associations with risk of
pancreatic cancer. Int J Mol Epidemiol Genet. 5:152–163.
2014.PubMed/NCBI
|
|
28
|
Yang S, Pinney SM, Mallick P, Ho SM,
Bracken B and Wu T: Impact of oxidative stress biomarkers and
carboxymethyllysine (an advanced glycation end product) on prostate
cancer: A prospective study. Clin Genitourin Cancer. 13:e347–e351.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xin M and Deng X: Nicotine inactivation of
the proapoptotic function of Bax through phosphorylation. J Biol
Chem. 280:10781–10789. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Semba S, Itoh N, Ito M, Harada M and
Yamakawa M: The in vitro and in vivo effects of
2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific
inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer
cells. Clin Cancer Res. 8:1957–1963. 2002.PubMed/NCBI
|
|
32
|
Hu L, Zaloudek C, Mills GB, Gray J and
Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition
by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin
Cancer Res. 6:880–886. 2000.PubMed/NCBI
|
|
33
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng J, Koh X, Hua F, Li G, Larrick JW
and Bian JS: Cardioprotection induced by Na+/K+-ATPase activation
involves extracellular signal-regulated kinase 1/2 and
phosphoinositide 3-kinase/Akt pathway. Cardiovasc Res. 89:51–59.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Q, Turner KM, Alfred Yung WK, Chen K
and Zhang W: Role of AKT signaling in DNA repair and clinical
response to cancer therapy. Neuro Oncol. 16:1313–1323. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Blume-Jensen P and Hunter T: Oncogenic
kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boudot C, Saidak Z, Boulanouar AK, Petit
L, Gouilleux F, Massy Z, Brazier M, Mentaverri R and Kamel S:
Implication of the calcium sensing receptor and the
Phosphoinositide 3-kinase/Akt pathway in the extracellular
calcium-mediated migration of RAW 264.7 osteoclast precursor cells.
Bone. 46:1416–1423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Granado MH, Gangoiti P, Ouro A, Arana L,
González M, Trueba M and Gómez-Muñoz A: Ceramide 1-phosphate (C1P)
promotes cell migration: Involvement of a specific C1P receptor.
Cell Signal. 21:405–412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wallesch M, Pachow D, Blücher C, Firsching
R, Warnke JP, Braunsdorf WEK, Kirches E and Mawrin C: Altered
expression of E-Cadherin-related transcription factors indicates
partial epithelial-mesenchymal transition in aggressive
meningiomas. J Neurol Sci. 380:112–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Prieto-García E, Díaz-García CV,
García-Ruiz I and Agulló-Ortuño MT: Epithelial-to-mesenchymal
transition in tumor progression. Med Oncol. 34:1222017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huber MA, Azoitei N, Baumann B, Grünert S,
Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-кB is
essential for epithelial-mesenchymal transition and metastasis in a
model of breast cancer progression. J Clin Invest. 114:569–581.
2004. View Article : Google Scholar : PubMed/NCBI
|
